Dr. Sharoon Qaiser, M.D.
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
800 Rose St, Mn472
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2014
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
KY license 52704 -
Neurology Physician
KY license R3595
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Kentucky Medical Services Foundation, Inc (967 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $218,703 in research payments for these studies, mostly to the institutions running them.
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Eli Lilly and Company · Active, not recruiting · NCT04616326 - A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05164172 - A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A S · Recruiting · NCT04965675 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company · Active, not recruiting · NCT03432286 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396574 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396236
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.